Latest Aquaculture News

Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.

Atlas Pearls reported increased pearl harvest and sales volumes for FY25, driving revenue growth to $44.3 million, though profits declined compared to the previous year. The company declared a fully franked final dividend, underscoring its solid financial footing.

Atlas Pearls Ltd reported a 6% revenue increase to $44.3 million in FY25 despite a 30% drop in net profit, unveiling a strategic roadmap targeting up to 50% production growth by FY30 alongside a fully franked dividend.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

BPH Global Ltd reports a robust 50.9% increase in seaweed sales for July 2025, driven by strong domestic demand in Indonesia and plans to expand internationally.

Carnegie Clean Energy launches a $3 million Share Purchase Plan to fuel commercialisation of its wave and MoorPower technologies, capitalising on growing global momentum in ocean energy.

Carnegie Clean Energy launches a $3 million Share Purchase Plan at a 20% discount to fund its pioneering 6 MW CETO wave energy project in Spain and expand its global footprint.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.